Table 1.
NUP98 fusions in leukemia.
| Fusion partner | Chromosome | Domain | Disease | Outcome | References |
|---|---|---|---|---|---|
| HOXA9 | 7p15 | HD | AML, CML, MDS, CMML |
Median OS: 13.5 months Median RFS: 6 months N fusion: 11 N total = 493 |
[53, 62, 63, 64, 65, 66] |
| HOXA11 | 7p15 | HD | CML, JMML | [67, 68] | |
| HOXA13 | 7p15 | HD | AML, CML, MDS | [62, 67, 69] | |
| HOXC11 | 12q13 | HD | AML | [70] | |
| HOXC13 | 12q13 | HD | AML | [70, 71] | |
| HOXD11 | 2q31 | HD | AML | [72] | |
| HOXD13 | 2q31 | HD | AML, CML | [62, 73, 74] | |
| GSX2 (Gsh2) | 4q12 | HD | AML | [75] | |
| PRRX1 (PMX1) | 1q23 | HD | AML, CML, MDS | [23, 76, 77] | |
| PRRX2 | 9q34 | HD | AML | [78, 79] | |
| POU1F1 | 3p11 | HD | AML | [80] | |
| JADE2 | 5q31 | PHD | APL‐AML, MDS‐MPN, JMML | [81, 82] | |
| PHF23 | 17p13 | Coiled domain‐PHD | AML | [83] | |
| HHEX | 10q23 | HD | AML | [84] | |
| NSD1 | 5q35 | SET‐PHD‐PWWP‐Coiled domain | MDS/MPN, AML, MPAL |
CR: 38% OS: 36% EFS: 17% RR: 64% N fusion: 108 N total = 2235 |
[14, 18, 85, 86, 87, 88] |
| NSD3 | 8p11 | SET‐PHD‐PWWP‐Coiled domain | MDS, AML | [24, 89] | |
| MLL (KMT2A) | 11q23 | SET‐PHD‐Ciled domain‐SET binding domain‐Bromodoamin | AML‐MDS | [90] | |
| ASH1L | SET, Bromo, PHD, BHD | AML, MDS | [91] | ||
| SETBP1 | 18q12 | SET binding domain | T‐ALL | [92] | |
| 17q23 | PHD‐Bromodomain‐CC | AMKL‐ T‐ALL | [93, 94] | ||
| KDM5A (JARID1A) | 12p13 | PHD‐Jumonji (Demethylase) | AMKL |
CR: 81% OS: 30% EFS: 25% RR: 68% N fusion = 32 N total = 2235 |
[18, 95] |
| MLLT10 (AF10) | 10p12 | OM‐LZ, Q‐rich | MDS | [75] | |
| ANKRD28* | 3p25 | Not identified | AML‐MDS | [96] | |
| DDX10 | 11q22 | Helicase domains‐CC | MDS, AML, CML | [97, 98] | |
| HMGB3 | Xq28 | HMG box‐CC | AML | [99] | |
| KAT7 (HBO1) | 17q21 | MYST‐CC | CMML | [62, 100] | |
| PSIP1 (LEDGF) | 9p22 | HMG box‐CC | MDS, AML, CML | [21, 101, 102, 103, 104] | |
| RAP1GDS1 | 4q21 | CC | T‐ALL, AML | [105, 106] | |
| RARA | 17q21 | DBD‐LBD | APL | [59] | |
| RARG | 12q13 | DBD‐LBD | AML | [58] | |
| TOP1 | 20q11 | Topoisomerase‐Coiled domain | AML, MDS | [107, 108] | |
| TOP2B | 3p24 | Topoisomerase‐ Coiled domain | AML | [109] | |
| VRK1 | 14q32 | Not identified | T‐ALL | [110] | |
| CCDC28A (C6orf80) | 6q24 | Coiled domain | T‐ALL, AML | [111] | |
| IQCG | 3q29 | Coiled domain, IQ | MPAL‐ T‐ALL | [25, 112] | |
| LOC348801 (LNP1) | 3q12 | Not identified | AML | [113] | |
| ADD3 | 10q25 | Coiled domain | T‐ALL, AML | [114] | |
| FN1 | 2q31 | Not identified | AML | [115] |
Abbreviations: AML, acute myeloid leukaemia; CR, complete remission; MDS, myelodysplastic syndrome; N, number; OS, overall survival; RFS, relapse‐free survival; RR, relapse risk.